UCB Pharma S.A. and Nodality, Inc. have announced a strategic collaboration utilizing Nodality’s proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds.
The agreement establishes a multi-year collaborative investigation focusing initially on immunology disorders.
Based on information generated using Nodality’s technology, the agreement also gives UCB the option to engage Nodality to develop companion diagnostics for UCB’s compounds.
The terms of the agreement, whose details are not disclosed, include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved.
In addition, Nodality may be eligible for royalties on future diagnostic sales.
David Parkinson, MD, Chief Executive Officer of Nodality, said, “We are delighted to be working together with UCB’s world class immunology research group to enhance their drug development activities. Based on Nodality’s extensive application of the SCNP platform to malignant and autoimmune diseases, we believe that we will be able to add significant value to UCB’s drug development portfolio. This collaboration is validation of Nodality’s unique technological approach and of the value the SCNP platform technology can bring to pharmaceutical drug development. We look forward to a close and productive working relationship with UCB’s research and development teams."
Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, “We look forward to the Nodality collaboration as we advance UCB’s Research & Development pipeline. This collaboration represents a key component of UCB’s strategy to innovate on the paradigm of drug development through an enhanced understanding of disease pathways and drug mechanisms in order to realize the potential for patient stratification, targeted treatments and improved care for patients.”